Oscar Health. Why I See Only Upside From Here

Oscar Health, Inc. (NYSE: OSCR), a technology-driven health insurance company, has long divided Wall Street analysts. While some see a speculative bet with unsustainable losses, others — like myself — view it as a misunderstood growth story with the potential to deliver exponential returns. If Oscar’s operational fears dissipate, and its valuation multiples expand to align with sector peers, I believe there is a realistic ~20X valuation upside over a multi-year horizon.

This report breaks down the rationale behind that claim, with comparative valuation, risk discounting, multiple expansion models, and a view of potential catalysts in 2025–2027.

Important: This article is not a recommendation to buy or sell. Readers should conduct their own research and consult a licensed financial advisor before making any trading decisions.

🏥 What is Oscar Health?

Oscar Health, founded in 2012 and headquartered in New York City, is a direct-to-consumer health insurer that leverages data science, a user-centric app experience, and telehealth-first models to challenge incumbents like UnitedHealth and Cigna.

As of FY2024, Oscar covers approximately 1.35 million members across 20 states, focusing heavily on Affordable Care Act (ACA) individual plans and Medicare Advantage markets. Their flagship platform — +Oscar — offers a SaaS-based service for third-party payers, aiming to license Oscar’s infrastructure for broader market use.

If Oscar’s operational fears dissipate, and its valuation multiples expand to align with sector peers, I believe there is a realistic ~20X valuation upside over a multi-year horizon.

💸 Current Valuation Snapshot (as of July 2, 2025)

Source: Yahoo Finance – Oscar Health, Morningstar

Compared to peers like Alignment Healthcare (ALHC) or Clover Health (CLOV), Oscar is trading at a deeply distressed valuation, largely due to fear over long-term profitability, cash burn, and regulatory risk.

📉 Why the Stock Is So Cheap

Oscar’s ultra-low valuation — a mere 0.10x sales — is an anomaly in a sector where growth peers trade anywhere from 1.5x to 4x sales. Several factors contribute to this discount:

1. Profitability Concerns Oscar remains unprofitable, though losses have narrowed. Markets are skeptical about the company ever achieving meaningful EBITDA margins.
2. Cash Burn and Funding Risk Oscar had ~$1.1 billion in cash at the end of FY2024 but burned over $250 million during the year. Concerns over future dilutive funding remain.
3. Regulatory Risk As an ACA-heavy player, Oscar is vulnerable to policy shifts. Investors recall the volatility under the Trump administration and fear future changes.
4. Small Float, High Volatility The stock is thinly traded, leading to exaggerated price movements and weak institutional confidence.

📈 Bull Thesis: Why the Market Is Wrong

Despite these concerns, the long-term bull case remains compelling. Here’s why:

1. Operating Leverage is Kicking In

Oscar’s medical loss ratio (MLR) improved to 83.2% in FY2024, from 89.7% in FY2023, indicating enhanced pricing discipline and better patient risk management. EBITDA losses halved. Operating leverage in a SaaS-style insurance model should compound.

2. +Oscar Platform Has SaaS-Level Margins

The +Oscar platform generated $97 million in SaaS revenue in 2024 and is forecasted to grow at 45% CAGR through 2027.

The +Oscar modern tech stack and operations allow us to deliver integrated, end-to-end health plan services with the administrative efficiency of far larger health plans. +Oscar enables provider-sponsored and regional health plans to overcome scale disadvantages and lower administrative spend, driving improved profitability.

Details: https://www.hioscar.com/plus-oscar

Once scaled, this segment could generate 30%+ EBITDA margins, a rarity in healthcare.

Source: Oscar Health Investor Presentation – Q1 2025

3. Valuation Arbitrage

If Oscar were to trade at even 2.0x forward sales, below the median of healthcare SaaS (3.5x) and managed care growth companies (2.7x), it would imply a $12.1 billion valuation on expected 2026 revenues of $6.05B.

That’s nearly 20X the current $625M market cap.

🔍 Valuation Models

📊 Base Case (Moderate Re-Rating)

• 2026 Revenue Estimate: $6.05B
• Valuation Multiple: 1.5x
• Implied Market Cap: $9.08B (~€8.42B)
• Upside: 14.5X

📈 Bull Case (SaaS Valuation Expansion)

• Valuation Multiple: 2.5x
• Implied Market Cap: $15.12B (~€14.01B)
• Upside: 24.2X

📉 Bear Case (Status Quo, No Rerating)

• Multiple: 0.15x
• Market Cap: $900M (~€835M)
• Upside: 1.44X

The risk-reward ratio skews dramatically in favor of upside, with minimal downside in a market already pricing bankruptcy-like outcomes.

📅 Key Catalysts Ahead

1. Profitability Milestone (FY2025 or FY2026) Management has guided for adjusted EBITDA breakeven by Q4 2025. If achieved, it would re-rate the stock meaningfully.
2. New State Expansions Oscar plans to enter three new states in 2026. More covered lives mean more data and higher margins at scale.
3. Strategic Licensing Deals for +Oscar Rumors persist around partnerships with regional Blue Cross affiliates. These could be high-margin revenue streams.
4. Tech Platform Spin-Off Analysts speculate that the +Oscar SaaS platform could be spun off or IPO’d separately — a potential $5B–$7B valuation event.

💥 Risks to the Thesis

Despite the potential upside, key risks persist:

• Regulatory Uncertainty: A repeal or major change to the ACA would hit Oscar hard.
• Profitability Misses: Failure to achieve breakeven in FY2025 could tank sentiment.
• Execution Errors: Rapid expansion can lead to MLR volatility and increased churn.
• Dilution: A capital raise under current prices would severely dilute shareholders.

🏁 Final Thoughts

Oscar Health presents an asymmetric investment opportunity. The company trades at bankruptcy-level multiples despite growing revenue, expanding margins, and a differentiated SaaS platform. If fears subside and the company continues on its current trajectory, even a conservative re-rating to industry-average multiples yields a 10X–20X return.

For patient investors willing to tolerate short-term volatility and political risk, Oscar Health could be a moonshot with real fundamentals.

📚 References

• Oscar Health Investor Relations
• Yahoo Finance – OSCR
• Morningstar Analyst Reports
• U.S. Centers for Medicare & Medicaid Services (CMS)
• PitchBook on Healthcare SaaS Multiples
• SEC Filings – Edgar